In a Friday interview with CNBC’s Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson explained how his company uses new AI technology to develop drugs.

Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.

Recursion's AI-Powered Drug Revolution Recursion is a clinical-stage TechBio company that is fundamentally built upon the principles of artificial intelligence and machine learning.

Shares of biotechnology stocks such as Recursion Pharmaceuticals (NASDAQ: RXRX), Summit Therapeutics (NASDAQ: SMMT), and CRISPR Therapeutics AG (NASDAQ: CRSP) plunged on Monday, down 9.4%, 5.6% ...